<DOC>
	<DOCNO>NCT00375492</DOCNO>
	<brief_summary>This trial design compare effect twice-daily exenatide twice-daily placebo weight loss . This trial evaluate overweight obese subject type 2 diabetes inadequate glycemic control metformin , sulfonylurea , metformin plus sulfonylurea . Subjects treat exenatide placebo addition current oral antidiabetes agent regimen participate lifestyle modification program .</brief_summary>
	<brief_title>Effect Weight Loss Exenatide Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes least 6 month Have treat stable dose follow least 6 week prior screen : *immediate extend release metformin , *a sulfonylurea , *a fixeddose sulfonylurea/metformin combination therapy Have HbA1c 6.6 % 10.0 % , inclusive Have Body Mass Index ( BMI ) 25 kg/m^2 39.9 kg/m^2 , inclusive Are treat follow excluded medication : *exogenous insulin , thiazolidinedione , alphaglucosidase inhibitor 1 week within 6 week screen ; *Symlin injection time ; * Byetta injection within 3 month screen discontinuation therapy time due adverse reaction ; *drugs directly affect gastrointestinal motility ; *use weight loss drug ( include available counter ) within 3 month screen ; *chronic ( lasting longer 2 week ) systemic corticosteroid ( exclude topical , intranasal , inhaled preparation ) oral , intravenous , intramuscular route within 2 month screen Have condition contraindicate metformin and/or sulfonylurea use Have change lipidlowering agent within 6 week screen Have receive glucagonlike peptide1 ( GLP1 ) analog , dipeptidyl peptidaseIV inhibitor ( DPPIV inhibitor ) previously participate study Have receive treatment within last 30 day drug receive regulatory approval indication time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>